Gladstone scientists reprogram skin cells into insulin-producing pancreas cells
A cure for type 1 diabetes has long eluded even the top experts. Not because they do not know what must be done—but because the tools did not exist to do it. But now scientists in the laboratory of Gladstone Institutes’ Investigator Sheng Ding, MD, PhD, harnessing the power of regenerative medicine, have developed a technique in animal models that could replenish the very cells destroyed by the disease. The team’s findings, published online today in the journal Cell Stem Cell, are an important step towards freeing patients from the life-long injections that characterize this devastating disease.
Type 1 diabetes, which usually manifests during childhood, is caused by the destruction of beta-cells (?-cells). ?-cells are a type of cell that normally resides in the pancreas and produces a hormone called insulin. Without insulin, the body’s organs have difficulty absorbing sugars, such as glucose, from the blood. Once a death sentence, the disease can now be managed with regular glucose monitoring and insulin injections. A more permanent solution, however, would be to replace the missing ?-cells. But these cells are hard to come by, so researchers have looked towards stem cell technology as a way to make them.
“The power of regenerative medicine is that it can potentially provide an unlimited source of functional, insulin-producing ?-cells that can then be transplanted into the patient,” said Dr. Ding. “But previous attempts to produce large quantities of healthy ?-cells—and to develop a workable delivery system—have not been entirely successful. So we took a somewhat different approach.”
One of the major challenges to generating large quantities of ?-cells is that these cells have limited regenerative ability; once they mature it’s difficult to make more. So the team decided to go one step backwards in the life cycle of the cell.
The team first collected skin cells, called fibroblasts, from laboratory mice. Then, by treating the fibroblasts with a unique ‘cocktail’ of molecules and reprogramming factors, they transformed the cells into endoderm-like cells. Endoderm cells are a type of cell found in the early embryo, and which eventually mature into the body’s major organs—including the pancreas, the home of ?-cells.
“Using another chemical cocktail, we then transformed these endoderm-like cells into cells that mimicked early pancreas-like cells, which we called PPLC’s,” said Gladstone Postdoctoral Scholar Ke Li, PhD, the paper’s lead author. “Our initial goal was to see whether we could coax these PPLC’s to mature into cells that, like ?-cells, respond to the correct chemical signals and—most importantly—secrete insulin. And our initial experiments, performed in a petri dish, revealed that they did.”
The research team then wanted to see whether the same would occur in live animal models. So they transplanted PPLC’s into mice modified to have hyperglycemia (high glucose levels), a key indicator of diabetes.
“Importantly, just one week post-transplant, the animals’ glucose levels started to decrease, and gradually approached normal levels,” continued Dr. Li. “And when we removed the transplanted cells, we saw an immediate glucose spike, revealing a direct link between the transplantation of the PPLC’s and reduced hyperglycemia.”
But it was when the team tested the mice eight weeks post-transplant that they saw more dramatic changes: the PPLC’s had given rise to functional, insulin-secreting ?-cells.
“These results not only highlight the power of small molecules in cellular reprogramming, and are proof-of-principle that could one day be used as a personalized therapeutic approach in patients,” explained Dr. Ding.
The Latest on: Type 1 Diabetes
via Google News
The Latest on: Type 1 Diabetes
- Health Watch: Living with Type 1 diabeteson January 10, 2020 at 6:28 pm
There are more than a million people who have Type 1 diabetes and they can expect to live at least ten years less than Americans without the disease. In fact, there are only 90 diabetics who have ...
- Researchers identify new prevention strategy for type 1 diabeteson January 9, 2020 at 12:02 pm
A protein newly identified as important in type 1 diabetes can delay onset of the disease in diabetic mice, providing a new target for prevention and treatment in people, according to research led by ...
- Pediatric type 1 diabetes, islet autoimmunity associated with changes in weight, heighton January 8, 2020 at 4:04 am
“There is still no clear picture of if and how the whole growth trajectory in early life is associated with the development of islet autoimmunity and type 1 diabetes. This is mainly due to the lack of ...
- The development of My Care Hub Mobile-Phone App to Support Self-Management in Australians with Type 1 or Type 2 Diabeteson January 8, 2020 at 2:13 am
Digital behavioural change interventions have the potential to provide education and motivate users to regularly engage with self-management of diabetes. This paper describes the development of My ...
- Genetic differences help distinguish type 1 diabetes in children from 'type 1.5' in adultson January 8, 2020 at 12:35 am
A multi-center team of researchers led by Children's Hospital of Philadelphia (CHOP) has discovered a genetic signature that could help distinguish an adult-onset form of diabetes sharing many type 1 ...
- Genetic differences distinguish Children's type 1 diabetes from Adults' type 1.5on January 7, 2020 at 10:56 pm
Latent autoimmune diabetes in adults (LADA) is often also known as 'type 1.5 diabetes' as it consists of characteristics of both T1D and type 2 diabetes (T2D). LADA produces auto-antibodies that ...
- Severe hypoglycemia contributes to diminished cognitive ability for older adults with type 1 diabeteson January 3, 2020 at 4:17 am
Cognitive abilities such as executive function, language and episodic memory are all negatively affected by severe hypoglycemia in adults with type 1 diabetes aged at least 60 years, according to ...
- High cost of insulin has life-threatening implications for patients with Type 1 diabeteson January 2, 2020 at 6:19 pm
This prohibitive cost is causing some U.S. patients with Type 1 diabetes to ration the amount of insulin they use, with life-threatening implications. The commentary by S. Vincent Rajkumar, M.D., a ...
- Diomics Corporation and University of California, Irvine Collaborate to Enable Cell Therapy Clinical Trial for Type 1 Diabeteson January 2, 2020 at 5:30 am
SAN DIEGO, CA, Jan. 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Diomics Corporation, a leader in forensic, diagnostic, and therapeutic science ...
- High Lipoprotein(a) Levels in Type 1 Diabetes Add to CVD Riskon December 30, 2019 at 7:04 am
In an observational registry study of Swedish outpatients with type 1 diabetes, those who had high plasma lipoprotein(a) [Lp (a)] levels — defined as >120 nmol/L or approximately 50 mg/dL — were more ...
via Bing News